Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Rapid Onsite Testing Reduces Emergency Department Transfers in Long-Term Care

By LabMedica International staff writers
Posted on 03 Aug 2026

Respiratory infections in long-term care residents frequently trigger emergency department transfers that strain hospital capacity and expose frail patients to additional risks. More...

Turnaround delays from off-site laboratory testing hinder rapid diagnosis and outbreak control in these congregate settings. These system gaps are most consequential during peak virus seasons when clinical deterioration can be swift. To help address this challenge, academic hospitals in Toronto and partners have evaluated onsite rapid testing within long-term care homes.

The intervention was assessed in the PROMPT-LTC trial, led by Sunnybrook Health Sciences Center with Michael Garron Hospital, Humber River Health, and the University of Toronto in partnership with 20 long-term care homes across Toronto. Published in JAMA Internal Medicine, the study used a desktop rapid-testing instrument operable by trained staff to detect COVID-19, influenza, and respiratory syncytial virus in under an hour. This contrasted with the usual three- to five-day turnaround when specimens were transported to external laboratories.

The trial was conducted during the 2024–2025 respiratory virus season. Half of the homes implemented onsite rapid testing, while the remainder continued standard off-site testing. Infection prevention and control teams from each hospital trained long-term care staff to integrate the testing into daily workflows; Baycrest served as one of the implementation sites.

Homes with onsite rapid testing performed more than twice as many tests and initiated influenza antivirals earlier. This improved detection translated into an 11% lower chance of transfer to a hospital emergency department for complications of respiratory infection, equivalent to four avoided emergency department visits per 100 beds over a respiratory virus season. According to the research team, if applied across Canada, the approach could avert an estimated 8,000 emergency department transfers between November and March, when hospitals are often overcrowded.

“Bringing hospital-level testing into LTC homes is a major improvement in quality of care for residents. Knowing that this approach improves resident outcomes and can free up health care capacity should justify the upfront cost,” said Jerome Leis, medical director of infection prevention and control at Sunnybrook and an associate professor of medicine in U of T’s Temerty Faculty of Medicine.

"By working across the health care sector and linking hospitals with LTC homes, we can innovate new and better ways of organizing care. We stop working across silos and start to see what is possible when we team up with a shared focus of providing resident-centered care," said Leis.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.